Surgical site infections (SSIs) — infections occurring within 30 days (or 90 days for implant procedures) of a surgical procedure — affect an estimated 160,000–300,000 patients annually in the United States, representing the most common healthcare-associated infection in surgical patients (38% of all HAIs in surgical patients) and costing $3.5–10 billion annually in attributable healthcare expenditures. SSIs increase hospital length of stay by 7–11 days, double the probability of ICU admission, and carry a 2–11× higher mortality risk. Despite this burden, SSIs are among the most preventable HAIs: systematic implementation of evidence-based bundles consistently achieves 40–60% risk reduction, with some high-performing centers achieving rates below 1% for clean-contaminated procedures.
The Core SSI Prevention Bundle
Preoperative antibiotic prophylaxis: appropriate antimicrobial agent selection (cefazolin for most procedures, with MRSA-active therapy for colonized patients), administration within 60 minutes before incision (30 minutes for fluoroquinolones and vancomycin), and re-dosing for prolonged procedures (cefazolin re-dose at 4h). Optimal timing adherence alone reduces SSI by 40–50% versus suboptimal timing. Normothermia: intraoperative hypothermia (core temp <36°C) impairs neutrophil function, increases vasoconstrictive ischemia at the wound, and impairs collagen synthesis. Forced-air warming and warmed IV fluids maintaining normothermia reduce SSI by 30–60% (KURZ NEJM 1996 landmark trial). Glucose control: hyperglycemia (>180 mg/dL) impairs neutrophil phagocytosis and significantly increases SSI risk in both diabetic and non-diabetic patients. Intraoperative insulin infusion targeting 140–180 mg/dL reduces SSI by approximately 40% in major surgery. Oxygen delivery: supplemental high-flow oxygen (FiO₂ 0.8) intraoperatively and for 2h postoperatively generates supraphysiological subcutaneous oxygen tension that potentiates neutrophil oxidative killing — the PROXI trial (2009, JAMA) demonstrated 40% SSI reduction with 80% vs. 30% FiO₂. Skin preparation: chlorhexidine-alcohol skin preparation demonstrates 41% SSI reduction compared to povidone-iodine (Darouiche NEJM 2010) — now recommended by AORN, CDC, and WHO as first-line. Hair removal: clipping (not shaving) immediately before surgery — shaving creates microabrasions that increase SSI risk 3× versus clipping.
Wound Closure and Postoperative Management
Wound closure technique and materials influence SSI risk: subcuticular closure with monofilament absorbable suture demonstrates lower SSI rates than staples for colorectal and abdominal procedures (meta-analysis 2017, JAMA Surgery: OR 0.61). Triclosan-coated sutures reduce SSI by 27% in meta-analysis (16 RCTs). Negative pressure wound therapy (NPWT) prophylactically over closed incisions in high-risk patients (obese, contaminated wound, redo surgery) reduces SSI by 33% in systematic review. Comprehensive wound care supply chains — including CHG-based skin prep, sterile wound closure materials, and NPWT systems — are critical for high-performance SSI prevention programs. Our wound care catalog includes chlorhexidine skin preparation, wound closure supplies, and sterile gloves for surgical teams committed to infection prevention excellence.
